Edward C Dempsey

US Patent:

20120121573, May 17, 2012

Filed:

Sep 1, 2011

Appl. No.:

13/224126

Inventors:

Edward C. Dempsey - Aurora CO, US

International Classification:

A61K 38/48
A61P 11/00
A61P 9/00
A61P 9/12
G01N 33/573
C12Q 1/68
C12Q 1/37
A61K 48/00
A61P 29/00

US Classification:

424 9467, 514 44 R, 435 74, 435 613, 435 612, 435 23, 435 618

Abstract:

The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.

US Patent:

62288431, May 8, 2001

Filed:

Apr 21, 2000

Appl. No.:

9/557038

Inventors:

Edward C. Dempsey - Denver CO

Assignee:

University Technology Corporation - Boulder CO

International Classification:

A01N 4304

US Classification:

514 31

Abstract:

A method for treating pulmonary and systemic vascular diseases associated with cardiac hypotrophy, dysfunction or failure that involves the administration of an effective amount of a PKC antagonist to a patient suffering from one of such diseases is disclosed. PKC antagonists are selected from bryostatin derivatives and more preferably from bryostatin-1. The disease states treatable in accordance with the present invention are characterized by alterations in vascular structure, vascular tone, myocardial hypotrophy, dysfunction or failure, idiopathic pulmonary hypertension and chronic hypoxic pulmonary hypertension. Particular formulations include bryostatin-1 in an effective amount to treat one or more of the above-referenced diseases.

US Patent:

20150093373, Apr 2, 2015

Filed:

Oct 9, 2014

Appl. No.:

14/510738

Inventors:

- DENVER CO, US
Edward C. DEMPSEY - Aurora CO, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE - DENVER CO

International Classification:

A61K 38/48
C12N 9/64
C12Q 1/37
A61K 31/7088
G01N 33/573

US Classification:

424 9467, 514 44 R, 435 74, 435 618, 435 612, 435 23, 506 9, 435 611

Abstract:

The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.